» Articles » PMID: 23541683

Toll-like Receptor 3 Expression Inhibits Cell Invasion and Migration and Predicts a Favorable Prognosis in Neuroblastoma

Overview
Journal Cancer Lett
Specialty Oncology
Date 2013 Apr 2
PMID 23541683
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

To evaluate the clinical significance of TLR3 expression on neuroblastomas, we performed immunohistochemical study on archival tissues and in vitro studies on neuroblastoma cell lines. The results showed that positive TLR3 expression was associated with favorable histology and prognosis. Activation of TLR3 by polyinosinic:polycytidylic acid [poly(I:C)] treatment is effective to suppress cell migration and invasion and to decrease organized assembly of F-actin and filopodia formation, in TLR3-expressing SK-N-AS cells, which could be reversed by TLR3-targeting siRNA treatment. TLR3 agonist poly(I:C) promotes GAP-43 expression also in SK-N-AS cells only. Taken together, TLR3 could serve to predict favorable behavior in neuroblastomas.

Citing Articles

Toll-like receptor 3: a double-edged sword.

Hsieh M, Nishizaki D, Adashek J, Kato S, Kurzrock R Biomark Res. 2025; 13(1):32.

PMID: 39988665 PMC: 11849352. DOI: 10.1186/s40364-025-00739-5.


An anoikis-related signature predicts prognosis and immunotherapy response in gastrointestinal cancers.

Liu R, Liu Y, Huang W, Chen P, Cheng Y Front Immunol. 2025; 16:1477913.

PMID: 39981252 PMC: 11839610. DOI: 10.3389/fimmu.2025.1477913.


Toll-Like Receptors and the Response to Radiotherapy in Solid Tumors: Challenges and Opportunities.

Haroun R, Naasri S, Oweida A Vaccines (Basel). 2023; 11(4).

PMID: 37112730 PMC: 10146579. DOI: 10.3390/vaccines11040818.


Epigenetic state determines inflammatory sensing in neuroblastoma.

Wolpaw A, Grossmann L, Dessau J, Dong M, Aaron B, Brafford P Proc Natl Acad Sci U S A. 2022; 119(6).

PMID: 35121657 PMC: 8832972. DOI: 10.1073/pnas.2102358119.


Methylation Regulation of on Immune Parameters in Lung Adenocarcinoma.

Li A, Wu H, Tian Q, Zhang Y, Zhang Z, Zhang X Front Oncol. 2021; 11:620200.

PMID: 34094905 PMC: 8173059. DOI: 10.3389/fonc.2021.620200.